VASH2 promotes cell proliferation and resistance to doxorubicin in non-small cell lung cancer via AKT signaling.

In conclusion, the findings in the present study indicate that VASH2 promotes NSCLC cell proliferation and resistance to doxorubicin via modulation of AKT signaling. Thus, we suggest that VASH2 may become a potential therapeutic target for the treatment of NSCLC. PMID: 30940294 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30940294?dopt=Abstract

Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study